ENDRA Life Sciences renewed its global collaboration agreement with GE Healthcare to develop ENDRA’s clinical platform Thermo-Acoustic Enhanced UltraSound.
ENDRA Life Sciences (NASDAQ:NDRAU) renewed its global collaboration agreement with GE Healthcare (NYSE:GE) to develop ENDRA’s clinical platform Thermo-Acoustic Enhanced UltraSound.
As quoted in the press release:
ENDRA’s TAEUS™ technology is being developed to enable existing ultrasound systems to visualize tissue function and composition, and monitor a variety of therapeutic interventions at the point of care. ENDRA believes these capabilities could have broad potential clinical applications, including non-invasively quantifying fat in the liver for early diagnosis and monitoring of Non-Alcoholic Fatty Liver Disease (NAFLD), which affects over one billion people worldwide. According to The LANCET, NAFLD has become the most common chronic liver disease, affecting 15–40% of the general adult population, and an important cause of cirrhosis and liver cancer worldwide.
Once approved, ENDRA’s multiple TAEUS™ clinical applications would have the potential to address a $12 billion global ultrasound market opportunity.
Under the terms of the agreement, GE Healthcare will support ENDRA’s efforts to commercialize its TAEUS™ technology for use in a fatty liver application by, among other things, providing equipment and technical advice, and facilitating introductions to GE Healthcare clinical ultrasound customers. In return for this assistance, ENDRA will afford GE Healthcare certain rights of first offer with respect to manufacturing and licensing rights for the target applications.